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Abstract: The concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to
disseminated cancer lesions while minimizing damage to healthy tissue and organs. Critical aspects for success-
ful development of novel radiopharmaceuticals for TRT are: i) the identification and characterization of suitable
targets expressed on cancer cells; ii) the selection of chemical or biological molecules which exhibit high affin-
ity and selectivity for the cancer cell-associated target; iii) the selection of a radionuclide with decay properties
that suit the properties of the targeting molecule and the clinical purpose. The Center for Radiopharmaceutical
Sciences (CRS) at the Paul Scherrer Institute in Switzerland is privileged to be situated close to unique infrastruc-
ture for radionuclide production (high energy accelerators and a neutron source) and access to C/B-type labora-
tories including preclinical, nuclear imaging equipment and Swissmedic-certified laboratories for the preparation
of drug samples for human use. These favorable circumstances allow production of non-standard radionuclides,
exploring their biochemical and pharmacological features and effects for tumor therapy and diagnosis, while
investigating and characterizing new targeting structures and optimizing these aspects for translational research
on radiopharmaceuticals. In close collaboration with various clinical partners in Switzerland, the most promising
candidates are translated to clinics for ‘first-in-human’ studies. This article gives an overview of the research
activities at CRS in the field of TRT by the presentation of a few selected projects.
Keywords: Folate, PSMA · Minigastrin · Radiopharmacy · Targeted radionuclide therapy · Terbium radio-
nuclides · Theragnostics
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The expensive infrastructure (e.g. cyclotron facilities, neu-
tron sources, Type A/B/C laboratories, and Swissmedic-certified
laboratories for the preparation of drug samples for human use)
and the highly specialized and complex know-how in accelera-
tor technology, accelerator physics, target development, radio-
chemistry, radiation protection and radiosyntheses suggest that
radiopharmaceutical research in Switzerland typically takes place
in an academic environment. On the other hand, the sometimes
extremely short half-lives of the employed radionuclides favor
the physical proximity of the facilities to the clinics. Recently,
Big Pharma began showing great interest in radiopharmaceuti-
cals for cancer therapy, in particular. Bayer successfully launched
the alpha-particle emitter 223RaCl
2
(Xofigo®) for the treatment
of osseous metastases in castration-resistant prostate cancer pa-
tients (CRPC),[1] while Novartis acquired Advanced Accelerator
Applications in 2018 after they completed a successful Phase
III clinical trial (NETTER-1 trial) with a [177Lu]Lu-labeled so-
matostatin analogue ([177Lu]Lu-DOTATATE, Lutathera®) for the
treatment of metastasized neuroendocrine tumors.[2] In the same
year, Novartis acquired Endocyte after they licensed [177Lu]Lu-
PSMA-617, a potential first-in-class radiopharmaceutical for the
treatment of metastatic castration-resistant prostate cancer pa-
tients (mCRPC) targeting the prostate-specific membrane antigen
(PSMA).[3] [177Lu]Lu-PSMA-617 is currently being investigated
in the Phase III global VISION clinical trial (ClinicalTrials.gov:
NCT03511664).[4]
At Paul Scherrer Institute (PSI), the Center for
Radiopharmaceutical Sciences (CRS) focuses on the develop-
ment of novel radiopharmaceuticals targeting the cholecystokinin
B receptor (CCKBR) and the folate receptor (FR), in particular.
At the same time, CRS is optimizing the structure of PSMA-
targeting agents with the aim to improve their pharmacological
profiles and, hence, increase their tumor uptake. Furthermore,
CRS has investigated the improved efficacy of the clinically-used
PSMA-617 with the engagement of innovative, therapeutic radio-
nuclides. This article describes selected examples of the research
endeavors at CRS, some of which were carried out together with
other academic research groups as well as industrial partners.
2. Developing Minigastrin Analogues from ‘Bench-to-
Bedside’
In the early 1940s, radioactive iodide (131I–) was used for treat-
ment of patients with hyperthyroidism as the first systemic radio-
therapy. Since 1946, radioactive iodide has become a standard di-
agnostic and therapeutic radiopharmaceutical for papillary or fol-
licular thyroid cancers,[5] however, not all thyroid cancer types take
up radioactive iodide. The most notable example in this regard is
medullary thyroid cancer (MTC), which does not accumulate iodide
due to its origin in parafollicular C-cells.[5] Limited therapy options
are, therefore, available. It is well documented, however, that MTC
cells frequently express CCKBR to which gastrin binds with high
affinity.[6]Radiolabeled gastrin analogues may, thus, serve as a ther-
apeutic option for these patients. The initial gastrin derivatives suf-
fered from a high kidney retention, which prohibited a therapeutic
application due to potential radionephrotoxicity (e.g.DTPAMG0,[7]
Table 1). The glutamic acid chain in the linker entity was identi-
fied as the reason for the high kidney uptake observed. As part of a
EuropeanCOSTAction (BM0607) consortium, twelve radiolabeled
CCKBR ligands were tested for their binding affinity, stability and




(PPF11) linker entities, respectively, showed
the best in vivo behavior with respect to high tumor uptake and low
kidney retention. This situation resulted in a tumor-to-kidney ratio
of 3.1 and 1.5, respectively, compared to 0.3 determined for the ref-





linker reduced the kidney uptake by
about 90%, with a retained high tumor uptake of 6.44% IA/g.
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1. Introduction
Targeted radionuclide therapy (TRT) is a promising therapeutic
modality for patients with non-operable tumors and tumor metas-
tases. As compared to ‘standard care’ chemotherapy and external
beam radiotherapy, TRT is thought to have fewer adverse events and
improved efficiency through targeting tumor-associated proteins
such as receptors, antigens or membrane-associated transporters.
The development of radiolabeled molecules that target such
cancer-related structures is a multidisciplinary approach. Expertise
in physics, radiochemistry, inorganic and organic chemistry, bio-
chemistry as well as pharmacology, pharmacy and medicine are
required. Chemical and biological lead structures with high affinity
and selectivity for a clinically relevant target have to be identified.
These lead structures are specifically modified to enable incorpora-
tion of the corresponding radionuclide without affecting the phar-
macokinetic properties and/or target binding affinity of the radio-
pharmaceutical. The selection of an appropriate radionuclide is also
critical, as it may have a profound impact on functionalization strat-
egies (e.g. covalent radiolabeling or via chelating agents suitable for
radiometals) of a targeting molecule as well as on the in vitro and in
vivo properties of the future radiopharmaceutical. Subsequently, the
radiopharmaceuticals are evaluated in vitro and in preclinical ani-
mal studies, including non-invasive small animal nuclear imaging.
Promising radiopharmaceuticals may qualify for clinical trials once
toxicological tests have been performed and robust and reproduc-
ible manufacturing processes have been established according to
the rules of Good Manufacturing Practice (GMP) (Fig. 1).
Fig. 1. Translational (‘bench-to-bedside’), radiopharmaceutical research
includes: i) development of new radionuclides for diagnosis and therapy;
ii) lead optimization; iii) in vivo, preclinical evaluation of new radiophar-
maceuticals; iv) production of radiopharmaceuticals in clean rooms; v)
clinical trials.
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application and; ii) with the 177Lu[Lu]-PPF11N, cancer lesions
that were not detected with computer tomography (CT) or mag-
netic resonance imaging (MRI) were visualized using scintigra-
phy and single proton emission computer tomography (SPECT;
(Fig. 3).[10]A phase I/b dose escalation study is currently ongoing.
177Lu[Lu]-PPF11Nwas recently licensed to Debiopharm – a phar-
maceutical company based in Switzerland.
3. Exploring New Therapeutic Radionuclides at PSI
Ideally, the type of radionuclide used in a therapeutic radio-
pharmaceutical is tailored to the specific type of cancer or even the
stage of the disease. Radionuclides that undergo α-decay produce
particles composed of two neutrons and two protons, whereas ra-
dionuclides that undergo β¯-decay emit energetic electrons from
their nuclei.[11] Some radionuclides can also emit conversion or
Auger electrons via secondary effects. α-Particles have high lin-
ear energy transfer (LET) – between 20–190 keV/µm – and are
capable of damaging DNA both directly and via the production of
radicals and reactive oxygen species. β¯-particles have lower LET
values of 0.2–2.0 keV/µm and mainly exert their therapeutic ac-
tion via production of free radicals in the cancer cell. Conversion
or Auger electrons possess LETs in the range of 4–26 keV/µm.
Particles with high and medium LET can be useful for TRT de-
pending on the size of themetastases and on the radiosensitivity of
the tumor cells. For example, the TRT of leukemia and lymphoma
typically requires particles of lower energy than it would be the
case for TRT of solid tumors (Fig. 4).
Therefore, the radionuclides’ physical properties signifi-
cantly contribute to a satisfactory therapeutic outcome in TRT.
Today, only a limited number of therapeutic radionuclides are
available for routine clinical TRT (e.g. yttrium-90, lutetium-177,
iodine-131, radium-223). Recently, researchers have started to
The sulfo-ether of the methionine side chain in peptides PPF10
and PPF11 was easily oxidized during the radiolabeling proce-
dure, leading to a significant loss of affinity towards the CCKBR
(10–40-fold reduction of IC
50
values compared to the non-oxidized
radiopeptides). Methionine was, therefore, replaced by a norleu-
cine, resulting in the peptides PPF11N and PPF10N (Table 1). The
177Lu-labeled PPF11N and PPF11Nwere comparedwith 177Lu[Lu]-
PPF10, 177Lu[Lu]-PPF11 aswell as with the respective oxidized de-
rivatives for receptor affinity by competition assay and biodistribu-
tion studies in mice bearing CCKBR-positive A431 tumors.[9] The
biodistribution results of 177Lu[Lu]-PPF11N showed an increased
tumor uptake compared to 177Lu[Lu]-PPF11 by a factor of more
than 2 (from 4.7±1.8 % IA/g to 11.0±2.5 % IA/g), which was not
observed for the 177Lu[Lu]-PPF10 derivative (Fig. 2).
Aclinical studywithpatients suffering frommetastasizedMTC
was initiated, in collaboration with the Department of Nuclear
Medicine at University Hospital Basel, in 2015 (ClinicalTrials.
gov: NCT02088645). The GMP-production of 177Lu[Lu]-PPF11N
was performed at PSI and the sterile injection solution sent to
the University Hospital Basel for application within 24 h after
production. The patients were initially injected with low activity
of radiopeptide for diagnostic and dosimetric purposes. The diag-
nostic study was promising in different aspects: i) the calculated
absorbed dose to the tumor and healthy organs favored therapeutic
Fig. 2. Biodistribution data of [177Lu]Lu-PPF10 and [177Lu]Lu-PPF11 and
their corresponding Nle-derivatives ([177Lu]Lu-PPF10N and [177Lu]Lu-
PPF11N) and those with the oxidized methionine ([177Lu]Lu-PPF10ox,
[177Lu]Lu-PPF10ox) in nude mice bearing CCKBR-transfected A431 xe-
nografts. The oxidized version lost affinity to CCKBR, which is reflected
by a low tumor uptake. There was no change observed in the tumor
uptake between [177Lu]Lu-PPF10 and [177Lu]Lu-PPF10N whereas the
change from [177Lu]Lu-PPF10 to [177Lu]Lu-PPF10N increased the tumor
uptake by more than two times.















Table 1. Amino acid sequences of
native minigastrin and the different
gastrin analogs (italic indicates
structural changes compared to
the lead compound MG0).
Fig. 3. (Center) Scintigraphy of patient performed 24 h after injection of
[177Lu]Lu-PPF11N. Specific uptake in the metastases of a medullary thy-
roid carcinoma and the stomach selected SPECT/CT in transversal slic-
es (Courtesy of the Dept. of Nuclear Medicine at the University Hospital
Basel, Prof. D. Wild and Dr. Ch. Rottenburger).
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disadvantages of these therapy concepts. Both of these radionu-
clides have great potential for clinical translation, as demonstrated
in our preclinical studies described in the sections that follow.
3.1 Terbium-161: A Potentially more Powerful
Alternative to Lutetium-177
Amajor focus of our research activities at the PSI over the last
decade has been the production and investigation of the terbium
radioisotopes.[14] Terbium is unique in that it comprises four med-
ically-interesting radioisotopes for all four modalities in nuclear
medicine. This includes positron emission tomography (PET, ter-
bium-152) and SPECT (terbium-155) imaging as well as targeted
α- (terbium-149) and β¯-radionuclide therapy (terbium-161). At
this development stage, terbium-161 is the most advanced radio-
isotope of the terbium family, not only in terms of production and
preclinical investigations, but also in view of a clinical transla-
tion. Herein, we summarize and discuss the achievements made
with terbium-161 at CRS and in collaboration with our external
partners.
Terbium-161 decays with a half-life of 6.953 d (recently de-
termined by Duran et al.[15]) by the emission of medium-energy
β¯-particles (Eβ¯
average
= 154 keV) and γ-radiation (Eγ = 48 keV, I
= 17.0%), 75 keV, I = 10.2%). In this regard, terbium-161 closely
resembles lutetium-177 (T
1/2
= 6.65 d, Eβ¯
average
= 134 keV, Eγ =
113 keV, I = 6.2% and 208 keV, I = 10.4%), the radiometal cur-
rently most often employed for TRT in clinics.[16] The medium
energy β¯-particles of lutetium-177 were revealed to be favorable
for the treatment of metastases, while preventing radionephro-
toxicity, as previously observed when using yttrium-90, a high-
energy β¯-particle emitter.[17] Terbium-161 is considered superior
to lutetium-177, due to the broader spectrum of emitted electrons.
In addition to the β¯-particles, terbium-161 also emits a substan-
tial number of short-range electrons, so-called conversion and
Auger electrons. These high-LET particles are of unique value
for the killing of single cancer cells, as they deliver a 3- to 4-fold
increased dose to spheres of subcellular dimensions.[18]
In an initial preclinical study, terbium-161 and lutetium-177
were compared using a DOTA-folate conjugate as a tumor-tar-
geting agent (Fig. 5A).[19] It was successfully demonstrated that
[161Tb]Tb-DOTA-folate reduced KB tumor cell viability more ef-
fectively than [177Lu]Lu-DOTA-folate when applied at the same
activity concentration (Fig. 5B). Even more intriguing was the ob-
servation that the tumor growth was more delayed in mice treated
explore the realm of suitable radionuclides for potential radio-
pharmaceutical and nuclear medical applications. In particular,
radionuclides with medium and high LET are the focus of atten-
tion. The Radionuclide Development group at PSI (a shared group
between CRS and Laboratory of Radiochemistry)[12] strives to pro-
duce novel radionuclides of high purity with specific decay proper-
ties that are superior to those that are currently used in the clinics.
The in vitro and in vivo characterization and application of these
radionuclides, in combination with different targeting molecules,
takes place at CRS. The interest of CRS lies, in particular, in the
production and investigation of radionuclides of the same element,
so-called radioisotopes, that can be employed either for diagnosis
or therapy and, thus, realizing the radiotheragnostics concept using
chemically identical radiopharmaceuticals. Among the most inter-
esting elements in this regard are scandium and terbium, as they
comprise several interesting radioisotopes for imaging purposes
(scandium-43/44 and terbium-152/155) and therapeutic application
(scandium-47 and terbium-149/161).[13] Scandium and terbium ra-
dionuclides are more suited than the use of pairs of unrelated radio-
metals, such as gallium-68 and lutetium-177 that are currently used
in routine clinical interventions for positron emission tomography
(PET) imaging and TRT. Terbium is also of interest to compare
effects of different types of particle emission for therapeutic pur-
poses. Terbium-161 emits β¯ particles and conversion and Auger
electrons, while terbium-149 emits α-particles. They may serve for
an in-depth investigation of therapeutic effects using chemically
identical radiopharmaceuticals to understand the advantages and
Fig. 4. Schematic presentation of the range of α-, β–-particles and Auger
(and conversion) electrons in tissue and their corresponding linear en-
ergy transfer (LET) ranges.
Fig. 5. (A) Chemical structure of
the DOTA-folate conjugate (cm09).
(B) Inhibitory effects of increasing
activity concentrations of [161Tb]
Tb-DOTA-folate (IC50 value: 0.014
± 0.013 MBq/mL) and [177Lu]Lu-
DOTA-folate (IC50 value: 0.063 ±
0.021 MBq/mL) in KB tumor cells
in vitro. (C) Survival curve of mice
treated with [161Tb]Tb-DOTA-folate
(median survival: 54 days) and
[177Lu]Lu-DOTA-folate (median sur-
vival: 35 days) as compared to un-
treated controls (median survival:
31 days); (D) SPECT/CT images
shown as maximum intensity pro-
jections (MIPs) 30 h after injection
of about 30 MBq [161Tb]Tb-DOTA-
folate and [177Lu]Lu-DOTA-folate,
respectively. The data were adapt-
ed from Müller et al., 2014, Eur J
Nucl Med Mol Imaging.[19]
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with [161Tb]Tb-DOTA-folate than when using [177Lu]Lu-DOTA-
folate, which resulted in a significantly increased survival of these
mice as compared to the group of mice treated with [177Lu]Lu-
DOTA-folate (Fig. 5C).[19] The possibility of utilizing the emit-
ted γ-radiation of terbium-161 for SPECT imaging was also suc-
cessfully demonstrated in a tumor-bearing mouse that received
[161Tb]Tb-DOTA-folate (Fig. 5D). The KB tumor xenografts were
visualized equally well in that mouse as was the case in a different
mouse injected with [177Lu]Lu-DOTA-folate.
More recently, the superiority of terbium-161 over lute-
tium-177 was demonstrated in prostate cancer cells that express
the prostate-specific membrane antigen (PSMA) using the clini-
cally-employed PSMA-617 ligand. It was shown that [161Tb]Tb-
PSMA-617 was significantly more effective in the killing of tu-
mor cells in vitro compared to [177Lu]Lu-PSMA-617 over a broad
concentration range (Fig. 6A).[20]These results received theMarie
Curie Award in 2018 from the European Association of Nuclear
Medicine (EANM) (Fig. 6B).
3.2 Terbium-149 – Theragnostics at its Best
Recent clinical data with targeted α-radionuclide therapy
(TAT) have revealed impressive results in mCRPC patients.[21]
TAT’s main advantage over β¯-particle therapy refers to the
α-particles’ higher LET over a short path of only 50–100 µm
that results in a higher relative biological effectiveness (RBE).
It is without doubt that the change in tumor burden before and
after TAT is impressive and, probably of unprecedented value in
the field of nuclear oncology. 225Ac-based TAT, however, raises
questions about potential undesired side effects as a result of the
complex decay chain of 225Ac, which results in several α- and β¯-
particle emissions from daughter nuclides. The so-called nuclear
recoil effect causes release of the daughter radioactive nuclei from
the targeting molecule and, thus, unwanted distribution of activ-
ity in the body, which may lead to radiotoxicity in healthy organs
and tissue.[22]







Its half-life of 4.1 h lies between bismuth-213 and actinium-225,
which makes terbium-149 interesting for use in combination with
fast-cleared small molecules that accumulate efficiently in the tu-
mor tissue and are rapidly cleared from background organs. The
decay chain of terbium-149 is considerably less complex than that
of actinium-225, resulting in only one α-particle emission (Eα =
3.97 MeV; I = 17%).[23] This may be advantageous with regard to
the safety profile of 149Tb-labeled radiopharmaceuticals.
In the literature, only few studies are reported that investigated
terbium-149 for therapeutic purposes. Among those is an article
of Beyer et al.who performed a preclinical experiment with 149Tb-
rituximab in a leukemia mouse model.[24] The study demonstrated
the feasibility to sterilize single cancer cells in circulation so that
the mice survived over a period of 4 months, while untreated
control mice developed tumor disease and reached the endpoint,
which required euthanasia.[24]
At CRS, terbium-149 was initially investigated in a proof-
of-concept study using a DOTA-folate conjugate.[25] A dose-
dependent inhibition of the KB tumor growth was observed in
mice treated with [149Tb]Tb-DOTA-folate, which led to a signifi-
cantly increased median survival time as compared to untreated
controls.[25] More recently, we were able to conduct a preclinical
study to investigate [149Tb]Tb-PSMA-617 with several groups of
PC-3 PIP tumor-bearing mice (Fig. 7A).[26] The resulting tumor
growth curve was more favorable when the radioligand was in-
jected twice (2 x 3 MBq) on two consecutive days as compared
to the effect of only one injection of the same total activity (1 x
6 MBq) (Fig. 7B). In both cases, the tumors did not, however,
entirely disappear which indicated the need for more frequent
injections. So far, it was not possible to further investigate and
optimize the administration scheme of [149Tb]Tb-PSMA-617 to
achieve tumor control over time, due to the limited availability of
terbium-149 both in terms of frequency and quantity.
A unique feature of terbium-149 refers to the co-emission
of β+-particles (positrons) of an energy (Eβ+
average
= 730 keV, I =
7.1%), suitable for PET imaging. The feasibility of PET imag-
ing using terbium-149 was demonstrated for the first time using
[149Tb]Tb-DOTANOC in a mouse model of somatostatin-express-
ing xenografts.[23] PET imaging was also successfully performed
with [149Tb]Tb-PSMA-617 in tumor-bearing mice that enabled
visualization of the PSMA-positive xenograft (PC-3 PIP tumor),
but not the PSMA-negative xenograft (PC-3 flu tumor) located on
the right and left shoulder of the mouse, respectively (Fig. 7C).[26]
Due to the β+-particle co-emission, direct monitoring of the
distribution of the radiopharmaceutical may be possible, which
would make the application of terbium-149 considerably more in-
teresting and safer than the use of currently employed α-particle-
emitting radionuclides such as actinium-225. Dose estimations
would be of unique value to better plan the following application
and minimize the risk of damage to healthy tissues and organs.
Although the preclinical data are scarce, terbium-149 is undoubt-
edly an interesting α-particle emitter with great potential for clini-
cal translation. Based on the experience gained from our research
with terbium-161, it has become obvious that the chemical and
Fig. 6. (A) Results of in vitro
cell viability studies performed
with [161Tb]Tb-PSMA-617 and
177Lu[177Lu]-PSMA-617. The favor-
able effect of terbium-161 over
lutetium-177 was demonstrated
by more effective reduction of cell
viability when [161Tb]Tb-PSMA-617
was used. The bars represent the
percentage of PC-3 PIP tumor
cell viability after exposure to
[161Tb]Tb-PSMA-617 and [177Lu]
Lu-PSMA-617, respectively, com-
pared to untreated control cells
(set to 100% viability; average ±
SD); (B) Marie Curie Award medal
received for the comparative study
of [161Tb]Tb-PSMA-617 and [177Lu]
Lu-PSMA-617.[20] The data were
adapted from Müller et al., Eur. J.
Nucl. Med. Mol. Imaging 2019.
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particular with oncologists and nuclear physicians, is essential in
order to identify the clinical needs and relevant indications that
should be addressed with TRT. Thirdly, radiopharmaceuticals are
among the few drug types which can be developed from ‘bench-
to-bedside’ by academia in a reasonable time period, as they are
applied in minute quantities and, thus, commonly well tolerated.
This was shown for most of the currently-approved radiopharma-
ceuticals including [177Lu]Lu-DOTATATE and radiopharmaceu-
ticals currently being tested in a Phase III clinical trial such as
[177Lu]Lu-PSMA-617. Meanwhile, conducting clinical trials has
become difficult, however, and eventually prohibitively expensive
for academic researchers, which were the main drivers for innova-
tion until today. To overcome this challenge, a closer interaction
and dialogue with the authorities will be necessary in order to find
pragmatic solutions for the clinical testing of new radiopharma-
ceuticals, taking into account the low risk potential and the high
benefit of this class of anticancer drugs.
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